An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer

The opioid receptor (OR) antagonist naltrexone inhibits estrogen receptor-α (ER) function in model systems. The goal of this study was to determine the clinical activity of naltrexone in patients with ER-positive metastatic breast cancer. Patients with hormone receptor positive metastatic breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayakumar, Jayanthi, Haddad, Tufia, Gupta, Kalpna, Sauers, Janet, Yee, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030534/
https://www.ncbi.nlm.nih.gov/pubmed/36441436
http://dx.doi.org/10.1007/s10637-022-01317-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030534/
https://www.ncbi.nlm.nih.gov/pubmed/36441436
http://dx.doi.org/10.1007/s10637-022-01317-4

Ejemplares similares